drugset
Drugs / CAB-ROR2-ADC
last change Dec 2024 re-read 3 minutes ago

CAB-ROR2-ADC

also known as BA3021

targets ROR2

Developed for
head and neck cancer · melanoma · non-small cell lung carcinoma · triple-negative breast carcinoma
Investigated by
BioAtla, Inc.

Trials 1

today NCT03504488 · Ph 1/2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03504488 Jun 2018 → Dec 2024 head and neck cancer, melanoma, non-small cell lung carcinoma, triple-negative breast carcinoma BioAtla, Inc. Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2024-07-23 BioAtla, Inc. BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck bioatla.com ↗
2022-01-10 BioAtla, Inc. BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors bioatla.com ↗
2018-06-28 BioAtla, Inc. BIOATLA ANNOUNCES FIRST PATIENT TREATED IN PHASE1/2 BA3021-001 CLINICAL TRIAL FOR CAB-ROR2-ADC THERAPEUTIC bioatla.com ↗
2018-04-16 BioAtla, Inc. BioAtla Announces FDA Clearance of Investigational New Drug Application For CAB-ROR2-ADC Therapeutic bioatla.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CAB-ROR2-ADC ClinicalTrials.gov intervention name — accepted as the source's own label NCT03504488 ↗
Known as BA3021 “This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active...” NCT03504488 ↗
Target ROR2 “Conditionally active biologic anti-ROR2 antibody drug conjugate” NCT03504488 ↗